Document:

EX-4.4

 Exhibit 4.4 

Agreement/Promissory Note 
 This
Agreement/Promissory Note is entered into as of April 28, 2016. The parties to this Agreement are Jillian and Curtis Helmer (Lender) and Genelux Corporation (Borrower). 

Lender hereby agrees to loan Borrower two million six hundred sixty thousand nine hundred twenty six dollars ($2,660,926). The funds for this loan have been
made available by Lender’s refinancing of personal property, and are therefore subject to costs, fees, prepaid interest, and hold backs, totaling four hundred sixty-five thousand twenty-eight dollars ($465,028), making the actual net payment
that will be wired to Genelux no later than May 1, 2016, two million one hundred ninety-five thousand eight hundred ninety-eight dollars ($2,195,898). 

This loan is subject to the following terms and conditions: 
  

	1.	 The loan will constitute senior debt of the borrower; 

 

	2.	 Lender shall receive a warrant certificate for the purchase of 532,185 shares of Genelux common stock at three
dollars ($3) per share, with an expiration date of May 1, 2026, in the form attached hereto as Exhibit “A”; 

  

	3.	 This Note will bear interest at the rate of 11.513% per year on any unpaid principal balance. The first six
months of interest is prepaid and nonrefundable; 

  

	4.	 The entire Note, including accrued unpaid interest will be due and payable on May 1, 2018;

  

	5.	 On May 1, 2017, interest only shall be paid to Lender in the amount of twenty-five thousand five hundred
thirty dollars ($25,530), with the same amount due on the first of each month thereafter until the Note is paid; 

  

	6.	 Late payment (more than seven days past due) of any amounts due under this Agreement shall be 10% of the past
due amount or fifty dollars ($50), whichever is greater. In the event of default on the loan, the interest rate shall increase by 6%; 

  

	7.	 Except for prepaid interest referenced in paragraph 3, Borrower may prepay this Note in whole or in part, prior
to maturity, without penalty; 

  

	8.	 It is understood that the purpose of this loan is to pay off pressing, high priority obligations owed by
Borrower – particularly, approximately one million five hundred thousand dollars ($1,500,000) ordered by the Delaware Chancery Court to be paid to Aladar Szalay for attorney fees and costs pursuant to Borrower’s indemnification policy.
Beyond that obligation, funds from the loan may be applied to operating costs or other business related expenses and goals of Borrower, in the sole discretion of Genelux management; 

	9.	 A further material consideration for this Agreement is that key management of Borrower (Genelux Corporation)
remain in place throughout the life of the loan. Key management means the present CEO/President of Genelux (Tom Zindrick), the Director of Investor Relations (Melodee Newbold), the Chairman of the Board (James Tyree), and Vice-Chairman of the Board
(George Vandeman). Lender reserves the right to call the loan and demand immediate repayment of the entire balance should key management change during the life of the loan, except in the event that the change in key management is due to a merger or
acquisition approved by Genelux shareholders; 

  

	10.	 Lender may, in its sole discretion, at any time during the life of the loan, convert part or all of the
principle balance plus accrued unpaid interest into common stock at $2.26 per share. Should lender elect to convert under this paragraph, Lender will be entitled, in addition to the shares purchased, to a warrant for twenty-five percent (25%) of the
purchased shares, exercisable at $3.00 per share for up to ten years from the date of purchase, so long as the amount converted is one million dollars or greater (in other words, if Lender converts $2.26 million of the loan into one million
shares of common stock, Lender will receive a warrant for an addition 250,000 shares of common stock); 

  

	11.	 This Agreement/Note shall be governed by the laws of the State of California; 

 

	12.	 In the event of any dispute or legal action required to enforce the terms of this Agreement, the prevailing
party shall be entitled to reasonable attorney fees; 

  

	13.	 This Agreement/Note represents the entire agreement and understanding of the parties. No other oral or written
representations have been made to induce the parties to enter into this Agreement. Any modifications or amendments to this Agreement/Promissory Note must be in writing, subscribed to by the parties. 

 

							
	 Dated: April 30, 2016
	 		 		 	 /s/ Jillian Helmer

		 		 		 	 Jillian Helmer

 

							
	 Dated: April 30, 2016
	 		 		 	 /s/ Curtis Helmer

		 		 		 	 Curtis Helmer

 

							
	 Dated: April 30, 2016
	 		 		 	 /s/ Thomas D. Zindrick

		 		 		 	 Thomas Zindrick

		 		 		 	 CEO/President

		 		 		 	 Genelux Corporation

 

 
 Amendment and Extension of Agreement/Promissory Note 

It is hereby agreed by and between the parties to the Agreement/Promissory Note (“Agreement” hereinafter) entered into on or about April 28,
2016, that said Agreement be modified as follows: 
  

	 	1.	 Term 4. of the Agreement is hereby amended to extend the due/payable date on the entire Note to May 1,
2021. 

  

	 	2.	 In addition to other payment terms set forth in the Agreement, $10,000 per month shall accrue, payable to
Lender by Borrower on the due date set forth in provision 1. above, or on the date that the Note is paid in full pursuant to term 7. of the Agreement. 

  

	 	3.	 The monthly $10,000 accrual set forth in provision 2. above shall not be considered part of the principle and
will not bear interest. 

  

	 	4.	 Lender may, at any time during the life of the Loan, convert the accrued payable balance set forth in provision
2. herein into common stock at $3.00 per share. 

  

	 	2.	 In all other respects the terms of the Note remain unchanged, and will be in full force and effect through
May 1, 2021. 

  

							
	Dated: 5/17/18	 		 		 	/s/ Jillian Helmer
		 		 		 	Jillian Helmer

  

							
	Dated: 5/17/18	 		 		 	/s/ Curtis Helmer
		 		 		 	Curtis Helmer

  

							
	Dated: 5/17/18	 		 		 	/s/ Thomas D. Zindrick
		 		 		 	Thomas Zindrick
		 		 		 	CEO/President
		 		 		 	Genelux Corporation

  

			
	 Genelux Corporation

	 Research and Development
 San Diego
Science Center
 3030 Bunker Hill Street, #310, San Diego, California 92109

858 483 0024 (tel) || 858 483 0026 (fax)
	  	 Office of Business and Investor Relations

1177 Idaho Street, #202, Redlands, California 92374
 909 307 9300
(tel) || 909 307 2251 (fax)

 Second Amendment and Extension of Agreement/Promissory Note 

It is hereby agreed by and between the parties to the Agreement/Promissory Note entered into as of April 28, 2016 (“Original Note”), and as
further amended on May 17, 2018 (collectively, the “Agreement” hereinafter), that said Agreement is modified, effective as of July 29, 2020, as follows: 
  

	 	1.	 The due date on the entire note is hereby extended to May 1, 2022 

 

	 	2.	 Effective as of July 29, 2020, Section 3 of the Original Note is hereby deleted in its entirety and
replaced with the following: “This Note will bear interest at the rate of 10.50% per year on any unpaid principal balance (equating to $23,283/mo as of the date of this Second Amendment and Extension of Agreement/Promissory Note)”.

  

	 	3.	 In all other respects the terms of the Note will remain unchanged, and will be in full force and effect through
May 1, 2022. 

  

							
	Dated: 12/8/2020	 		 		 	/s/ Jillian Helmer
		 		 		 	Jillian Helmer

  

							
		 		 	
				
	 Dated: 12/8/2020
	 		 		 	 /s/ Curtis Helmer

		 		 		 	 Curtis Helmer

  

							
	Dated: 12/8/2020	 		 		 	/s/ Thomas D. Zindrick
		 		 		 	Thomas D. Zindrick
		 		 		 	President and CEO
		 		 		 	Genelux Corporation

  

			
	 Genelux Corporation

	 Research and Development

San Diego Science Center
 3030 Bunker Hill Street, #310, San
Diego, California 92109
 858 483 0024 (tel) || 858 483 0026 (fax)
	  	 Office of Business and Investor Relations

1177 Idaho Street, #202, Redlands, California 92374
 909 307 9300
(tel) || 909 307 2251 (fax)EX-4.5

 Exhibit 4.5 
  

 
 UMBRELLA AGREEMENT REGARDING _______ FAMILY INVESTMENTS IN GENEUX CORPORATION 

This umbrella agreement (“Agreement”) is entered into this ___ day of ____ between Genelux Corporation, 3030 Bunker Hill Street, #310, San Diego, CA
92109 (hereafter “Company”) and the following individuals and entities (collectively, the “_______”): 
  

	
	
                      
              

	
                      
              

	
                      
              

  

	A.	 RECITALS 

  

	 	1.	 Due to an urgent need for significant funding to maintain operations pending receipt of a large investment
which was unexpectedly delayed, the ______ have agreed to total investments totaling $_______ in exchange for Company extending 25% warrant coverage on common stock purchases or conversions to common stock made pursuant to the Stock Purchase
Agreement and Convertible Note Purchase Agreements referenced in Paragraph A.2 hereinbelow and attached as exhibits to this Agreement. 

  

	 	2.	 Individual Agreements 

	 	a.	 _______ wishes to purchase a $______ Convertible Promissory Note with a maturity date which is thirty-six (36) months from the Effective Date of said Convertible Note (Exhibit A); and 

  

	 	b.	 _______ wishes to purchase a $______ Convertible Promissory Note with a maturity date which is thirty-six (36) months from the Effective Date of said Convertible Note (Exhibit B); and 

  

	 	c.	 _______ wishes to purchase a $______ Convertible Promissory Note with a maturity date which is thirty-six (36) months from the Effective Date of said Convertible Note    (Exhibit C); and 

The total of the _______’ proposed investments set forth above amounts to $_____. 

 

	B.	 PURPOSE OF AGREEMENT 

The purpose of this agreement is not to supplant the terms or representations in individual Convertible Note Purchase Agreements or Common
Stock Purchase Agreements between Company and the Parties to this Agreement. Rather, it is to insure that all Parties understand that the cumulative amount of their investments is consideration for the 25% Warrant coverage. Without a minimum total
investment of $500,000 being received under the combined individual agreements of this Umbrella Agreement, any Warrant coverage provided for in the individual agreements with individuals and entities referenced in Paragraph A hereinabove is null and
void. 

  
 1 

	C.	 AGREEMENT 

  

	 	1.	 It is hereby agreed among the Parties to this Umbrella Agreement that the Warrant coverage referenced in
Paragraph A.1. hereinabove, and further described in each investment agreement referenced in Paragraph A.2 hereinabove, is conditioned upon total funding, pursuant to agreements referenced in Paragraph A.2, being received by Company by _______,
2019. 

  

	 	2.	 It is further agreed that the total invested funds under the combined individual agreements of this Umbrella
Agreement must be no less than $500,000 in order for the Company to provide 25% Warrant coverage to each investing party. 

  

	 	3.	 As long as the initial investment pursuant to this Umbrella Agreement exceeds $500,000, subject to approval by
Genelux, individual notes may be amended to increase the amount of any individual loan. Such additional amount will also be eligible for the 25% warrant coverage specified in Paragraph A.1. herein. 

This Umbrella Agreement represents the entire and final agreement and understanding among the Parties with respect to the subject matter thereof and the
transactions contemplated, and supersedes any and all prior oral or written agreements pertaining to the subject matter. It may not be modified without the written consent of all Parties hereto. 

LENDERS’ NAMES 
  

	
	
                      
                      

	 [name]

	
	
                      
                      

	 [name]

	
	
                      
                      

	 [name]

  

	
	 GENELUX CORPORATION

 

	 By: _________________________

	 Thomas D. Zindrick

	 President and CEO

  

					
	 WITNESS
	  		  	ATTEST
			
	 	  		  	 
	 Melodee Newbold
	  		  	E. Nathan Schilt, J.D.
	 Vice President, Investor Relations
	  		  	Corporate Secretary

  
 2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00346-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00346-of-00352.parquet"}]]